Katoch K, Katoch V M, Natarajan M, Gupta U D, Sharma V D, Singh H B
Medical Unit I, National JALMA Institute for Leprosy and Other Mycobacterial Diseases (ICMR), Department of Health Research, Ministry of Health and Family Welfare, Government of India, Dr M Miyazaki Marg, Tajganj, Agra-282001, India.
Indian J Lepr. 2008 Oct-Dec;80(4):331-44.
This study was initiated in consultation with the National Leprosy Eradication Programme (NLEP) in mid nineties to try new treatment regimens for leprosy which were more robust in terms of control of reactions, long term relapses, operationally easier to undertake and feasible in field conditions. It was also envisaged to see if the addition of newer bactericidal drugs would be beneficial.
(i) To test the feasibility, safety and response of the patients to the new regimen. (ii) To observe the incidence of reactions during and after stoppage of therapy, for a period of 8-10 years after release from treatment.
A total of one hundred skin smear positive MB patients (15 LL, 35 BL and 50 BB) patients were included in this study. All the patients received the standard MDT + once a month supervised 100 mg of Minocycline and 400 mg of Ofloxacin for 12 months during the treatment phase. Thereafter, the treatment was stopped in all the patients which were followed-up on placebo (B complex tablets). Of these, 70 patients completed the treatment schedule of one year therapy and the post treatment follow-up of 9 to 10 years.
All the patients tolerated the drugs well. The clinical response of the patients to the treatment was very good of which 32.85% of cases had history of reactions before starting treatment. During treatment, the incidence of reactions increased marginally to 38.5%, but these were easily controlled with concurrent administration of steroids. After completion of treatment the incidence was much less i.e. 10% and 3% after 1 and 2 years of post treatment follow-up respectively. The overall relapse rate is 5.7% (4/70) with an incidence density of 0.05/100 patient years. Relapses were confirmed by clinical, bacteriological, molecular biological (rRNA probes and 36 kD targeting PCR) as well as ATP bioluminescence. The relapsed patients presented with the appearance of new lesions, slit-skin smears were again found to become positive after becoming negative. Three of the four cases who relapsed had the initial mean BI of 2 to 2.9+ whereas one had the initial mean BI of 1.5+. Also, 2 of the 4 relapsed patients had positive PCR signals at the time of stoppage of treatment.
The addition of Minocycline and Ofloxacin to the standard FDT has been observed to be a well tolerated. Overall as of now, the incidence of reactions observed with the newer treatment regimen is found to be significantly lower than that of 2 years fixed duration MB-MDT. The efficacy of this regimen regarding bacteriological clearance and relapse rates could not be compared due to non-availability of the results of experience with standard 1 year MDT regimen. However, this regimen appears to be operationally feasible and safe for the users.
本研究于九十年代中期与国家麻风病消除计划(NLEP)协商启动,旨在尝试新的麻风病治疗方案,这些方案在控制反应、长期复发方面更有效,操作上更简便且在现场条件下可行。还设想看看添加更新的杀菌药物是否有益。
(i)测试新方案对患者的可行性、安全性和反应。(ii)观察治疗期间及停药后8至10年的反应发生率。
本研究共纳入100例皮肤涂片阳性的多菌型(MB)患者(15例瘤型(LL)、35例界线类偏瘤型(BL)和50例界线类(BB))。所有患者在治疗阶段接受标准的多药联合化疗(MDT)+每月一次监督服用100毫克米诺环素和400毫克氧氟沙星,持续12个月。此后,所有患者停药,改用安慰剂(复合维生素B片)进行随访。其中,70例患者完成了一年的治疗计划及9至10年的治疗后随访。
所有患者对药物耐受性良好。患者对治疗的临床反应非常好,其中32.85%的病例在开始治疗前有反应史。治疗期间,反应发生率略有上升至38.5%,但通过同时使用类固醇很容易控制。治疗完成后,发生率低得多,即治疗后随访1年和2年时分别为10%和3%。总复发率为5.7%(4/70),发病密度为0.05/100患者年。通过临床、细菌学、分子生物学(rRNA探针和靶向36 kD的聚合酶链反应)以及ATP生物发光法确诊复发。复发患者出现新病变,皮肤涂片在转阴后再次呈阳性。4例复发患者中有3例初始平均细菌指数(BI)为2至2.9+,而1例初始平均BI为1.5+。此外,4例复发患者中有2例在停药时PCR信号呈阳性。
已观察到在标准的固定剂量联合化疗(FDT)中添加米诺环素和氧氟沙星耐受性良好。总体而言,截至目前,新治疗方案观察到的反应发生率明显低于2年固定疗程的多菌型MDT。由于无法获得标准1年MDT方案的经验结果,无法比较该方案在细菌学清除和复发率方面的疗效。然而,该方案对使用者而言在操作上似乎是可行且安全的。